新聞與活動
Nov 11, 2025
Onward Therapeutics Completes Share Exchange and Establishes Global Headquarters in Taiwan
Oct 28, 2025
Onward Therapeutics Exercises Exclusive Option and Signs Worldwide License Agreement with Institut du Cancer de Montpellier for Novel Onco-Metabolism Program
Apr 22, 2025
Onward Therapeutics Announces IMPD Approval for Its Subsidiary Emercell to Start Clinical Investigation of Allogeneic NK Cell Therapy OT-C001 in Combination with Rituximab
Jan 24, 2024
Onward Therapeutics Announces Enrollment of Phase 1 Clinical Trial of a Novel Bispecific Antibody (OT-A201) Targeting Two Immune Checkpoints
Jul 24, 2023
Emercell NK-001 (OT-C001) project selected as part of France 2030 plan “Biotherapies and bioproduction of innovative therapies"
Apr 10, 2023
Onward Therapeutics To Present at the Swiss Biotech Day 2023 on April 25, 2023
Sep 23, 2022
Emercell and Cell-Easy Sign a Strategic Agreement for the Scale-up and Manufacturing of NK-001
Jun 20, 2022
Onward Therapeutics Makes a Strategic Investment in EMERCell for Their NK Cell Technology for Immunotherapy
Jun 08, 2021
Onward Therapeutics Signs an Exclusive Collaboration and Worldwide Option and License Agreement with Institut du Cancer de Montpellier
May 04, 2021
Onward Therapeutics SA opened a wholly owned affiliate, Onward Therapeutics France SAS in Paris, France
Feb 17, 2021
Onward Therapeutics Makes a Strategic Investment in EMERCell for Their NK Cell Technology for Immunotherapy
Feb 16, 2021
Onward Therapeutics and Biomunex Pharmaceuticals Enter into a Worldwide Exclusive License and Co-development Agreement to a Bispecific Antibody for Immuno-Oncology